Kuchikala Reddy, MD
Gastroenterology · Philadelphia, PANPI 1992848519
Payments from drug & device makers
Across 401 payments — averaging $16,127 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$4.5M
- Gilead$470K
- E.r. Squibb & Sons, L.L.C.$338K
- GSK$317K
- Bausch Health US, LLC$179K
- Grifols Therapeutics LLC$141K
- plus $525K from 18 others
Across 1 payment — averaging $3900.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Spark Therapeutics, Inc.$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 31 | $4,497,123 |
| Gilead | 98 | $469,724 |
| E.r. Squibb & Sons, L.L.C. | 15 | $337,785 |
| GSK | 91 | $317,229 |
| Bausch Health US, LLC | 25 | $178,923 |
| Grifols Therapeutics LLC | 19 | $141,007 |
| Mallinckrodt Enterprises LLC | 19 | $117,894 |
| Regeneron | 20 | $96,952 |
| Merck | 33 | $70,810 |
| Bard Peripheral Vascular, Inc. | 4 | $57,353 |
| Intercept Pharma Europe Ltd. | 5 | $52,102 |
| Sequana Medical US Inc. | 3 | $48,652 |
| Pfizer | 11 | $23,177 |
| Spark Therapeutics, Inc. | 4 | $15,872 |
| Intercept Pharmaceuticals, Inc. | 6 | $14,970 |
| Daiichi Sankyo Inc. | 8 | $8,403 |
| AbbVie | 1 | $8,395 |
| Ipsen Biopharmaceuticals, Inc | 2 | $5,112 |
| AMAG Pharmaceuticals, Inc. | 1 | $2,800 |
| Theratechnologies Inc. | 1 | $2,000 |
| Grifols Biologicals LLC | 1 | $547 |
| Medtronic | 1 | $167 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $57 |
| ERBE USA Inc | 1 | $10 |
How this compares
$6,467,063 in reported general payments places this provider in the 95th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Philadelphia
- Dina Halegoua de MarzioPhiladelphia$1.5M
- Gary FalkPhiladelphia$1.4M
- Kristle LynchPhiladelphia$1.3M
- Gary WuPhiladelphia$931K
- Faten AberraPhiladelphia$909K
- Ben StangerPhiladelphia$815K
- David KaplanPhiladelphia$737K
- Stacey PrennerPhiladelphia$577K
- Mark OstermanPhiladelphia$410K
- Michael KochmanPhiladelphia$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.